40 companies. 10,000 people. One ecosystem shaping the future of medicine.
We joined the Flagship Pioneering 25th anniversary celebration — the first time the full ecosystem gathered in one place. As Boston Mayor Michelle Wu noted, among the 40 #FlagshipFounded companies are nearly 10,000 people driving innovation across Massachusetts and beyond.
Together, we are guided by a daring “What if?” and a shared commitment to plan backwards from the future we want to live in — making bold leaps today to build a healthier tomorrow and a better world.
#ThisIsGenerate | #BiggerLeaps
This Sunday at #ERS2025 in Amsterdam, Prof. Dave Singh will present Phase 1 results for GB-0895 as a late-breaker.
▪️ Date/Location: 15:45–17:00, September 28, 2025, Amsterdam, the Netherlands
▪️ Session: Cutting-edge trial data on biologic for airway diseases: asthma, COPD, chronic rhinosinusitis with nasal polyps and chronic cough
▪️ Presentation Title: GB-0895, a high-affinity anti-TSLP mAb, demonstrates prolonged half-life and sustained pharmacological activity supporting every 6‑month dosing in asthma
▪️ Presenter: Prof. Dave Singh, MD — Professor of Clinical Pharmacology & Respiratory Medicine at the University of Manchester, Medical Director at the Medicines Evaluation Unit in Manchester, and principal investigator of the Phase 1 study
View our abstract on the ERS website → https://lnkd.in/eKMryq4E#GenerativeAI | #LungHealth
Nearly 300 million people live with asthma worldwide. As #WorldLungDay is observed today, we’re sharing a new Q&A with Laurie A. Lee, our Chief Medical Officer for Immunology & Inflammation. We spoke with Laurie, a physician and clinical leader with deep experience in respiratory medicine, about where unmet need still exists, how GB-0895 — our AI-engineered antibody for severe asthma — could fit more naturally into patients’ lives with the potential for twice-yearly dosing, and her perspective on the future of this space.
Read Laurie’s interview for her perspective on patient needs, clinical evidence, and the future of respiratory care → https://lnkd.in/en5TyP5A
What if an antibody engineered with #AI could make six-month dosing possible for patients with severe asthma?
Today, we announced that Phase 1 results for GB-0895 will be presented as a late-breaker at #ERS2025 in Amsterdam this Sunday.
GB-0895 is an investigational anti-TSLP antibody studied in 96 patients with mild to moderate asthma. In this trial, it was well tolerated, showed an ~89-day half-life, and delivered sustained biomarker reductions consistent with blocking TSLP — findings that support the potential for an every six-month regimen in severe asthma.
Explore the mechanism below and get the full details in the news release → https://lnkd.in/eiuEEgCZ#GenerativeAI | #LungHealth
The Boston Globe Media’s “Future of Medicine 2025” captures how Boston’s biotech community is pushing science into uncharted territory — and reshaping patient care worldwide. From #AI-designed medicines to RNA editing to reversing the biology of aging, this ecosystem is setting the pace for what comes next.
We’re part of that momentum, using #GenerativeAI to create protein therapeutics from scratch. As our CEO Michael Nally told the Globe: “If you think about all the medical progress we’ve made over the past 100 years, I believe AI could enable a comparable leap in the next decade. That’s what gets us out of bed in the morning: the potential for massive impact on humanity.”
Read how Boston is shaping the next century of medicine → https://lnkd.in/eawuFHwZ#ProgrammingBiology | #ThisIsGenerate
Proud to represent the team at Generate:Biomedicines at the Fast Company Best Workplaces for Innovators awards reception. I really appreciate that Fast Company has recognized the tireless work of our scientists and professionals as we look to leverage generative biology to save and improve the lives of many.
Welcome, Laurie Lee, M.D.—our new Chief Medical Officer, Immunology & Inflammation.
A board-certified pediatrician and allergist-immunologist, Laurie brings more than 17 years leading late-stage development and regulatory approvals. She served as vice president, R&D, Transplant & Immunology at CSL Behring, where she led global clinical programs, including the largest placebo-controlled study in antibody-mediated rejection. Earlier at GSK, she advanced respiratory and allergy programs through late-stage development and regulatory submissions, and served as a faculty member in pediatrics at Duke University.
In her new role, Laurie will lead our I&I clinical portfolio as we advance novel protein therapeutics through trials—including GB-0895 for severe asthma, which is advancing toward later-stage trials. She’ll connect our platform to rigorous, patient-centered development and decisive execution.
Read the full announcement → https://lnkd.in/evz-AQms#ProgrammingBiology | #PatientsCantWait
Tomorrow in Montréal, Senior Principal Scientist Jeffrey Mitchell will join the scientific program at the 17th Protein Expression in Animal Cells Conference (PEACe) Conference with a poster: “Challenges and Opportunities in Discovery of Large Molecule Therapeutics Designed with Generative Artificial Intelligence (AI) Technology.”
PEACe is the biennial forum for recombinant protein expression—small by design, rigorously technical, and built for real exchange. It’s where expression systems, engineering, and quality meet.
Jeffrey will share how #GenerativeAI now proposes sequences at speed; why protein production, purification, and analytics can become the new bottleneck; and how building the right #ProteinSciences capability helps close that gap—moving ideas toward working molecules with rigor and repeatability.
Learn more: https://lnkd.in/eVESTEUe#PEACeConference2025 | #ProteinExpression
Birthday Week is a reminder of who we are and how we work. We set the standard high, deliver against it, and then raise the bar again. Last night, our CEO Michael Nally hosted our "Spicy Awards Soirée" — the signature event of the week and our moment to honor the people and teams who embody that spirit.
🏆 Anniversary Awards honored colleagues marking their five-year anniversaries — Adam Root, Benjamin Manning, Brett Blakeley, Frank Poelwijk, Olivia Schlepphorst, and Tanvi Gawde — whose dedication has shaped our progress from the early years to today.
🏆 Inventor Awards recognized Max Baranov, Zak Costello, Gevorg Grigoryan, John Ingraham, and Wujie Wang for inventions that make generative biology possible. Their work reflects more than individual achievement — it secures the foundation of our science, fuels discovery, and ensures our innovations can reach patients.
🏆 The CEO Award went to Andrew Robertson, Kapil Mayawala, Karima Amiri, Lovely Goyal, Sacha Prashad, PhD, and Victoria Szenes, DNP for raising the bar in how models, data, and experiments come together to advance medicine creation.
🏆 The Chairman’s Award, presented on behalf of our Chairman Noubar Afeyan, recognized Christopher Ng Thow Hing, Erin Yang, Ph.D., Grace Marden, Hayden Gruber, Hideki Shishido, Ph.D., João V. Rodrigues, Julia A. Jones, Mark Benhaim, Radhika Nayak Kennedy, and Xueyin Wang for daring to ask "what if" questions that open new possibilities for science and for patients.
These awards are reminders that progress comes from bold questions, urgency with purpose, continuously raising the bar, and working fiercely united to do what hasn’t been done before.
If this is how you want to work, join us: https://lnkd.in/gv9Ve3fd#ThisIsGenerate | #NowWeCan
